Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · May 21, 2021

Amantadine ER Significantly Increases ON Time With No Dyskinesia

Frontiers in Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

Frontiers in Neurology
Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
Front Neurol 2021 Mar 26;12(xx)645706, RA Hauser, RR Walsh, R Pahwa, D Chernick, AE Formella

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading